IMMUNOHISTOCHEMICAL DETERMINATION OF EXPRESSION OF SOMATOSTATIN RECEPTORS TYPES 1, 2A, 3 AND 5 IN NEUROENDOCRINE TUMORS OF VARIOUS LOCALIZATION AND GRADE
Background: Prediction of clinical benefits of somatostatin analogues in patients with neuroendocrine tumors (NET) is very important prior to their administration. Data on immunohistochemical assessment of the expression of somatostatin receptors (SSR) of various types, obtained from large samples o...
Main Authors: | L. E. Gurevich, N. A. Korsakova, I. A. Voronkova, V. E. Ashevskaya, A. G. Titov, L. M. Kogoniya, A. V. Egorov, T. A. Britvin, I. A. Vasil'ev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
MONIKI
2016-12-01
|
Series: | Alʹmanah Kliničeskoj Mediciny |
Subjects: | |
Online Access: | https://www.almclinmed.ru/jour/article/view/427 |
Similar Items
-
Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
by: Maria Celeste Cantone, et al.
Published: (2021-02-01) -
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
by: Kiesewetter, B., et al.
Published: (2022) -
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
by: Yuheng Hu, et al.
Published: (2021-05-01) -
Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
by: Beata Polowczyk, et al.
Published: (2020-07-01) -
Evaluation of the expression of somatostatin receptors by immunohistochemistry in neuroendocrine tumors of the small intestine
by: Paweł Gut, et al.
Published: (2020-05-01)